Cherwell publishes guide on environmental monitoring processes and validation
Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.
Cherwell Laboratories, specialist supplier of products for environmental monitoring and process validation, has drawn on its in-depth pharmaceutical and related industry knowledge to publish an eBook titled, “The Environmental Monitoring Processes and Validation Guide.”
The new guide (available to download from Cherwell’s website) has been created following the release of the revised draft of EU GMP Annex 1 – Manufacture of Sterile Medicinal Products. It is intended to assist sterile product manufacturers with reviewing and improving their environmental monitoring (EM) programs in preparation for the proposed changes to Annex 1.
The comprehensive guide highlights the most business-efficient EM measures organisations can take to comply with the latest iteration of the EU GMP Annex 1, and practical steps they can take to create the ideal EM process. It also addresses and summarises the key changes proposed to Annex 1 and covers: Why the EU GMP Annex 1 draft has been proposed; how it helps all industries move closer towards a global standard; how to prepare for compliance; examples of best practice for EM programs and the right tools needed for an effective and compliant program.
Andrew Ramage, Cherwell Laboratories’ Microbiology Product Specialist comments: “The draft copy of the new version of EU GMP Annex 1 has considerably more detail on the expectations of designing and implementing an environmental monitoring regime. It remains to be seen how much will change following the public consultation. Regardless of what changes are made, our in-depth guide will help the end user to interpret the new guidelines and to create and implement a robust environmental monitoring regime for their cleanroom, whatever the size of their facility.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance